New and Emerging Therapies in Psoriasis

被引：0

作者：

Leonardi, Craig L. ^{[1
,2
]}

Gordon, Kenneth B. ^{[3
]}

机构：

[1] St Louis Univ, St Louis, MO 63103 USA

[2] Cent Dermatol, St Louis, MO 63117 USA

[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA

来源：

SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2014年 / 33卷

关键词：

Apremilast; brodalumab; interleukin-12/23; inhibitors; interleukin-17; ixekizumab; JAK; Janus kinase inhibitors; phosphodiesterase-4; psoriasis treatment; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; CHRONIC PLAQUE PSORIASIS; TO-SEVERE PSORIASIS; DOUBLE-BLIND; USTEKINUMAB; SAFETY; EFFICACY; TRIAL;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blacker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blacker) and tofacitinib (a Janus kinase inhibitor). (C) 2014 published by Frontline Medical Communications

引用

页码：S37 / S41

页数：5

共 50 条

[21] Biologics switch in psoriasis
Wang, Ting-Shun
Tsai, Tsen-Fang
IMMUNOTHERAPY, 2019, 11 (06) : 531 - 541
[22] Emerging therapies for ulcerative colitis
Hanzel, Jurij
Hulshoff, Melanie S.
Grootjans, Joep
D'Haens, Geert
EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2022, 18 (05) : 513 - 524
[23] Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
Phan, Celine
Beneton, Nathalie
Delaunay, Juliette
Reguiai, Ziad
Boulard, Claire
Fougerousse, Anne-Claire
Cinotti, Elisa
Romanelli, Marco
Mery-Bossard, Laure
Thomas-Beaulieu, Domitille
Parier, Josiane
Maccari, Francois
Perrot, Jean-Luc
Ruer-Mulard, Mireille
Bastien, Marie
Begon, Edouard
Samimi, Mahtab
Jacobzone, Caroline
Quiles-Tsimaratos, Nathalie
Descamps, Vincent
Steff, Maud
Bilan, Paul
Vermersch-Langlin, Annie
Kemula, Mathilde
Amazan, Emmanuelle
Kupfer-Bessaguet, Ingrid
Cottencin, Anne-Caroline
Prignano, Francesca
Livideanu, Bulai
Gottlieb, Jeremy
Beauchet, Alain
Mahe, Emmanuel
ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 1 - 4
[24] Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab
Zhao, Yue
Lai, Wei
PATIENT PREFERENCE AND ADHERENCE, 2014, 8 : 865 - 872
[25] Current and Emerging Therapies for Itch Management in Psoriasis
Stull, Carolyn
Grossman, Shoshana
Yosipovitch, Gil
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2016, 17 (06) : 617 - 624
[26] New biologics for psoriasis and psoriatic arthritis
Rozenblit, Mariya
Lebwohl, Mark
DERMATOLOGIC THERAPY, 2009, 22 (01) : 56 - 60
[27] Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
Loos, Anne M.
Liu, Shanshan
Segel, Celia
Ollendorf, Daniel A.
Pearson, Steven D.
Linder, Jeffrey A.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (01) : 135 - +
[28] AFUTURE PERSPECTIVES IN THE TREATMENT OF PSORIASIS News In Biological Therapies
Diamantino, Filipa
Ferreira, Ana
ACTA MEDICA PORTUGUESA, 2011, 24 (06): : 997 - 1004
[29] Comparing biological therapies in psoriasis: implications for clinical practice
Griffiths, C. E. M.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2010, 24 : 10 - 14
[30] Ustekinumab induces rapid clearing of erythrodermic psoriasis after failure of antitumour necrosis factor therapies
Santos-Juanes, J.
Coto-Segura, P.
Mas-Vidal, A.
Osuna, C. Galache
BRITISH JOURNAL OF DERMATOLOGY, 2010, 162 (05) : 1144 - 1146

← 1 2 3 4 5 →